WINTON GROUP Ltd Acquires Shares of 49,700 Adaptive Biotechnologies Corporation $ADPT

WINTON GROUP Ltd acquired a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 49,700 shares of the company’s stock, valued at approximately $807,000.

Other large investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its position in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares during the period. Assetmark Inc. boosted its position in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares during the period. Smartleaf Asset Management LLC lifted its stake in Adaptive Biotechnologies by 593.5% in the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after acquiring an additional 3,371 shares during the period. Clearstead Advisors LLC grew its holdings in Adaptive Biotechnologies by 1,545.6% during the 4th quarter. Clearstead Advisors LLC now owns 3,752 shares of the company’s stock worth $61,000 after acquiring an additional 3,524 shares in the last quarter. Finally, Caxton Associates LLP bought a new position in Adaptive Biotechnologies during the 1st quarter worth about $93,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ADPT has been the topic of several recent research reports. TD Cowen increased their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. BTIG Research reiterated a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Finally, Morgan Stanley dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.57.

Insider Activity

In other Adaptive Biotechnologies news, CFO Kyle Piskel sold 3,115 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $13.04, for a total transaction of $40,619.60. Following the completion of the sale, the chief financial officer directly owned 256,725 shares of the company’s stock, valued at approximately $3,347,694. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Francis Lo sold 39,741 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $17.49, for a total transaction of $695,070.09. Following the sale, the insider directly owned 250,934 shares of the company’s stock, valued at approximately $4,388,835.66. The trade was a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 535,714 shares of company stock valued at $7,756,708. Corporate insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $17.07 on Thursday. Adaptive Biotechnologies Corporation has a 1 year low of $9.90 and a 1 year high of $20.76. The firm’s 50-day moving average is $14.41 and its two-hundred day moving average is $15.67. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -51.73 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.20) earnings per share. On average, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.